Thomas Hope, MD, is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He is also the Associate Chair for Joint Ventures for Radiology. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center. He also serves as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. From 2008-2012, Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford Medical Center in 2013.
Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors at UCSF.
An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. He current serves as principal investigator on grants from the NIH, the Prostate Cancer Foundation. He is the recipient of numerous accolades in molecular imaging, including the Henkin Fellow and Marc Tetalman Memorial Award from the Society of Nuclear Medicine and Molecular Imaging, the Young Investigator Award from the Prostate Cancer Foundation and the Wylie J. Dodds Research Award from the Society of Abdominal Radiology.
Abdominal Imaging and Nuclear Medicine, and Molecular Imaging and Therapeutics
Novel imaging agents, PET/MR, prostate cancer, neuroendocrine tumor, targeted radiotherapy
Education and Training:
• Medical School: Stanford University School of Medicine, California
• Internship: Kaiser Permanente, San Francisco, California
• Residency: University of California, San Francisco - Diagnostic Radiology
• Fellowship: Stanford Medical Center, California - Body MRI and Nuclear Medicine
• California Medical License
• American Board of Radiology, Certificate in Diagnostic Radiology
• American Board of Nuclear Medicine, Certificate in Nuclear Medicine